References
- Sadler JE, Budde U, Eikenboom JCJ, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4(10):2103–2114.
- Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160–174.
- Ingerslev J, Hvitfeldt Poulsen L, Sorensen B. Current treatment of von Willebrand’s disease. Hamostaseologie. 2004;24(1):56–64.
- Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis. 2005;16(Suppl 1):S17–S21.
- Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232.
- Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances. 2021;5(1):301–325.
- Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis. 2005;16(Suppl 1):S23–S26.
- Federici AB, Barillari G, Zanon E, et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010;16(1):101–110.
- Castaman G, Goodeve A, Eikenboom J. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98(5):667–674.
- Peyvandi F, et al. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfus. 2019;17(5):391–398.
- Federici AB. Prophylaxis in patients with von Willebrand disease: who, when, how? J Thromb Haemost. 2015;13(9):1581–1584.
- Sholzberg M, Khair K, Yaish H, et al. Real-world data on the effectiveness and safety of wilate for the treatment of von Willebrand disease. TH Open. 2021;5(3):e264–e272.
- Holm E, Zetterberg E, Lövdahl S, et al. Patients referred for bleeding symptoms of unknown cause: does evaluation of Thrombin generation contribute to diagnosis? Mediterr J Hematol Infect Dis. 2016;8(1):e2016014.
- Rugeri L, Beguin S, Hemker C, et al. Thrombin-generating capacity in patients with von willebrand's disease. Haematologica. 2007;92(12):1639–1646.